Vancouver, British Columbia – June 11, 2013 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced it has enrolled its first patient in a Phase 1/2 clinical trial of QBECO SSI for the treatment of Crohn’s disease. The company recently launched the Crohn’s disease clinical trial and is actively recruiting participants with moderate-to severe Crohn’s disease.
We are encouraged by the preliminary results of sustained remission of Crohn’s disease in some patients that were treated with QBECO SSI in a small compassionate use program and hope to achieve the same level of efficacy in this larger, controlled study,” said Dr. Hal Gunn, CEO of Qu Biologics. QBECO SSI aims to stimulate the innate immune system to remove the underlying trigger for this disease and therefore, presents a possible new treatment option for people living with Crohn’s disease,” added Dr. Gunn.
Ten patients with Crohn’s disease have been treated with QBECO SSI in a compassionate use program. All ten patients reported improvement in symptoms while on SSI treatment. Seven of the ten patients reported full resolution of clinical symptoms with a course of SSI treatment of three months or more. Four of these patients have had sustained clinical remission after discontinuing all medication including SSI treatment. The longest case of clinical remission reported is still ongoing after almost three years.
Three patients reporting ongoing sustained remission after stopping all treatment have had follow-up colonoscopies or CT scan with confirmation of full remission. These patients were treated under a “compassionate” use program, not a controlled blinded clinical trial and therefore, these results do not provide proof of benefit.